» Articles » PMID: 15003189

Pathogenicity of Anti-ganglioside Antibodies in the Guillain-Barré Syndrome

Overview
Journal Autoimmun Rev
Publisher Elsevier
Date 2004 Mar 9
PMID 15003189
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Guillain-Barré syndrome (GBS) is a postinfectious inflammatory polyradiculo-neuropathy characterized by flaccid paralysis. Antibodies directed against glycolipid structures (gangliosides), which are highly expressed in the peripheral nervous system, are frequently detected in sera from GBS patients. These antibodies interfere with nerve conduction and have been shown to activate phagocytes via IgG receptors (FcgammaR). These findings support an important role of glycolipid-specific antibodies in the pathogenesis of GBS.

Citing Articles

Fc-gamma IIIa-V158F receptor polymorphism contributes to the severity of Guillain-Barré syndrome.

Hayat S, Babu G, Das A, Howlader Z, Mahmud I, Islam Z Ann Clin Transl Neurol. 2020; 7(6):1040-1049.

PMID: 32484314 PMC: 7317642. DOI: 10.1002/acn3.51072.


Guillain-Barré syndrome in Colombia: where do we stand now?.

Mahecha M, Ojeda E, Vega D, Sarmiento-Monroy J, Anaya J Immunol Res. 2016; 65(1):72-81.

PMID: 27421717 DOI: 10.1007/s12026-016-8816-8.


Pathophysiological actions of neuropathy-related anti-ganglioside antibodies at the neuromuscular junction.

Plomp J, Willison H J Physiol. 2009; 587(Pt 16):3979-99.

PMID: 19564393 PMC: 2756433. DOI: 10.1113/jphysiol.2009.171702.